- Policy
- Reviewing 1 year of Rare Disease Support Scheme
- by Eo, Yun-Ho Nov 4, 2019 03:09pm
- Now is the time to take a greater interest in and discover issues of rare disease treatment coverage. The Moon Care’s ‘reimbursement expansion on the non-reimbursed’ would mean nothing for rare disease without ‘awareness’ of the nature. The reason behind tough rare disease treatment reimbursement listing seems complicated, but it
- Policy
- First year of Rare Disease Support Scheme
- by Eo, Yun-Ho Nov 4, 2019 08:13am
- The biggest issue of the policy is ‘lack of interest’. ‘Rare disease’ is not a specific categorization, but rather it is designated based on frequency of diagnosis. Korea defines ‘rare disease’ as a disease diagnosed to less than 20,000 people. With small patient size and lack of drug, these diseases are in dire need of new drug. B
- Policy
- Industry burdened but accepting of mandatory DSUR
- by Byun Kyung A Oct 31, 2019 09:59am
- Pharmaceutical industry initially complained of administrative strain when the government issued a notice on enforcing mandatory drug safety update report (DSUR)’, as advised by the National Assembly. But the industry also agrees with Korean government’s intention to enforce the pre-marketing regulation, which now has become a global tren
- Policy
- Weighted pricing benefit abused as permanent price booster
- by Byun Kyung A Oct 31, 2019 09:58am
- The government evaluated the current weighted drug pricing system has been digressed as a permanent pricing benefit. Apparently, 96 percent of items have maintained the benefitted pricing for more than three years, and the authority sees that such practice has distanced itself from the initial objective to secure stable supply. Ministry
- Policy
- For reimbursed drug, efficacy and cost-efficiency come first
- by Byun Kyung A Oct 31, 2019 09:34am
- On the last day of the 20th National Assembly Annual Audit for the Health Insurance Review and Assessment Service (HIRA), half the questions were dedicated to pharmaceutical affairs. The lawmakers of the NA Health and Welfare Committee questioned HIRA about NHI reimbursement reevaluation on dementia treatment choline alfoscerate, reimbu
